Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Preston, Australia Clinical Trials

A listing of Preston, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (271) clinical trials

A Phase 3 Multi-Center Randomized Double-Blind Placebo-Controlled Study of Fostamatinib Disodium in the Treatment of wAIHA

The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Phase

6.21 miles

Learn More »

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery

Subjects will be recruited in two sequential cohorts: the first 90 randomized subjects will undergo a right heart catheterization (RHC) with measurement of pulmonary vascular resistance (PVR) at Week 20 and will constitute the hemodynamic cohort; the remaining participants will constitute the non-hemodynamic cohort; they will undergo the same overall ...

Phase

6.21 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNF-IR) subjects with active Psoriatic Arthritis (PsA).

Phase

6.87 miles

Learn More »

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

Phase

6.87 miles

Learn More »

A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).

Phase

7.0 miles

Learn More »

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

Phase

7.0 miles

Learn More »

A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

The study consists of 3 sub-studies, as follows: Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in subjects with moderately to severely active Crohn's disease (CD) who responded to risankizumab induction treatment in Study M16-006 or Study M15-991 ...

Phase

7.0 miles

Learn More »

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adult participants with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug ...

Phase

7.0 miles

Learn More »

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.

Phase

7.0 miles

Learn More »

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Study duration per participant is approximative 62 weeks including up to a 4-week screening period, 52-week treatment period and 6-week follow-up period.

Phase

7.0 miles

Learn More »